Allogene Therapeutics (ALLO) Receives a Buy from William Blair

By Ryan Adsit

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Allogene Therapeutics (ALLOResearch Report). The company’s shares closed last Monday at $27.98.

According to, Prasad is a 5-star analyst with an average return of 13.1% and a 54.0% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and Rocket Pharmaceuticals.

Allogene Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $34.00, representing a 17.2% upside. In a report released yesterday, Canaccord Genuity also initiated coverage with a Buy rating on the stock with a $36.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $35.55 and a one-year low of $23.37. Currently, Allogene Therapeutics has an average volume of 365.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.